About the Company
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on IOVANCE BIOTHERAPEUTICS, INC.
Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the most promising penny stocks under $5. On August 8, Wells Fargo ...
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’
The approval from Health Canada is conditional, pending results of trials to confirm the immunotherapy’s clinical benefit.
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
PD-1 Inactivated TIL Cell Therapy (IOV-4001): Results are anticipated in the second half of 2025 from the Phase 2 efficacy portion of the IOV-GM1-201 trial in previously treated advanced melanoma.
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
Iovance is investigating Amtagvi in frontline advanced melanoma in the Phase 3 trial, TILVANCE-301 (NCT05727904), as well as in additional solid tumor types. About Iovance Biotherapeutics, Inc.
Health Canada approves Iovance’s Amtagvi for the treatment of advanced melanoma
Health Canada approves Iovance’s Amtagvi for the treatment of advanced melanoma: San Carlos, California Wednesday, August 20, 2025, 09:00 Hrs [IST] Iovance Biotherapeutics, Inc.
1IOVA : Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What&...
Iovance stock fell over 29% pre-market after Q2 results, despite reporting a strong revenue jump led by Amtagvi sales.
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public ... - Nasdaq
--Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, today ...
IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc ... - Morningstar
IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA) ...
IOVA COURT REMINDER: Iovance Biotherapeutics, Inc ... - Morningstar
News GlobeNewswire IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud — Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA) ...
IOVA STOCK ALERT: Iovance Biotherapeutics, Inc. Shareholders With ...
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ ...
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $21.07 Consensus ...
Iovance Biotherapeutics has a 1 year low of $5.05 and a 1 year high of $18.33. The stock has a market capitalization of $1.76 billion, a PE ratio of -3.88 and a beta of 0.53.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $20.25 Average ...
Robert W. Baird cut their target price on Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Friday, February 28th.
Similar Companies
Loading the latest forecasts...